ArticleEvidence-based complementary and alternative medicine : eCAM2022
Lucidumol A, Purified Directly from
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Targeting CDK2 and AURKA with Cerevisterol fromInternational journal of molecular sciences · 2026Article
- Parasitisterols A-C, 24,25-Dihydroxycholestane-Type Triterpenoids, from Oomycete Fish PathogenACS omega · 2026Article
- RETRACTION: Lucidumol A, Purified Directly fromEvidence-based complementary and alternative medicine : eCAM · 2026Article
- Potential Active Compounds ofFood science & nutrition · 2025Review
- Unlocking the therapeutic potential of bioactive compounds in3 Biotech · 2025Review
- Critical Review on the Anti-Tumor Activity of Bioactive Compounds from Edible and Medicinal Mushrooms over the Last Five Years.Nutrients · 2025Review
- Natural compounds modulate the mechanism of action of tumour-associated macrophages against colorectal cancer: a review.Journal of cancer research and clinical oncology · 2024Review
- Selective Antineoplastic Potential of Fractionated Caribbean NativePharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
- Retracted
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a deadly disease regardless of sex, and a few therapeutic approaches have been fully developed at advanced stages, even if some strategies have durable clinical benefits, such as immunotherapy and chemotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.